Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Pulse Biosciences (PLSE) Income from Continuing Operations (2020 - 2025)

Pulse Biosciences has reported Income from Continuing Operations over the past 6 years, most recently at 19366000.0 for Q3 2025.

  • Quarterly results put Income from Continuing Operations at 19366000.0 for Q3 2025, down 52.73% from a year ago — trailing twelve months through Sep 2025 was 32471000.0 (up 927.71% YoY), and the annual figure for FY2025 was 72800000.0, up 35.82%.
  • Income from Continuing Operations for Q3 2025 was 19366000.0 at Pulse Biosciences, down from 19168000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for PLSE hit a ceiling of 87800000.0 in Q4 2024 and a floor of 19366000.0 in Q3 2025.
  • Median Income from Continuing Operations over the past 5 years was 13996000.0 (2022), compared with a mean of 6553947.37.
  • Biggest five-year swings in Income from Continuing Operations: soared 429.21% in 2023 and later tumbled 68.39% in 2025.
  • Pulse Biosciences' Income from Continuing Operations stood at 15416000.0 in 2021, then soared by 40.34% to 9197000.0 in 2022, then soared by 429.21% to 30277000.0 in 2023, then skyrocketed by 189.99% to 87800000.0 in 2024, then crashed by 122.06% to 19366000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 19366000.0 (Q3 2025), 19168000.0 (Q2 2025), and 16795000.0 (Q1 2025) per Business Quant data.